Obesity and overweight cost European economies billions of euros a year, industry says

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-25T14:21:46.375Z • Permanent link

Recent findings by a prominent pharmaceutical industry association have shed light on a pressing issue affecting European economies. Obesity and overweight are causing significant financial burdens, equivalent to what some countries spend on housing or defence. According to data from the European Commission, over 57% of the adult population in the EU exceeds the recommended body mass index (BMI) threshold, resulting in substantial healthcare costs. A recent report by the European Pharmaceutical Industry Federation (EFPIA) estimates that obesity-related expenses in the EU alone exceed €200 billion annually.

Leading researchers and health experts have long been aware of the alarming rise in obesity rates across the continent. Dr. Catherine Deneen, a renowned nutritionist at the University of Cambridge, notes that "the European Union has implemented various policies to address obesity, including taxes on sugary drinks and unhealthy food, but more needs to be done to tackle the root causes of this epidemic." Industry leaders, too, recognize the need for concerted action. Mark Fox, CEO of GlaxoSmithKline, emphasized that "obesity is a major driver of healthcare costs, and we must work together to develop effective treatments and prevention strategies.

The EFPIA report highlights the need for policymakers to adopt a more comprehensive approach to addressing obesity. The association's research suggests that lifestyle interventions, such as increased physical activity and healthier eating habits, are essential in preventing and managing obesity. By investing in these initiatives, European governments can reduce the economic burden of obesity and improve the overall health of their populations. Governments and industry leaders are already taking steps to address this issue. The European Commission has announced plans to launch a new obesity strategy, which will focus on promoting healthy lifestyles and providing access to effective treatments.

The impact of obesity on European economies is far-reaching, affecting not only healthcare costs but also the broader economy. According to a study by the World Health Organization (WHO), obesity-related healthcare costs in the EU can range from 2% to 5% of GDP. This translates to significant economic losses for individual countries. For instance, the UK's National Health Service (NHS) estimates that obesity-related healthcare costs are around 8% of its annual budget. The financial burden of obesity is also felt by companies, which must contend with increased healthcare costs and lost productivity.

The pharmaceutical industry is also keenly aware of the economic implications of obesity. Companies like Novartis and Merck have developed obesity treatments, such as the GLP-1 receptor agonist semaglutide, which has been shown to be effective in reducing body weight. However, the development and marketing of these treatments are subject to regulatory scrutiny, and companies must navigate complex pricing and reimbursement systems. Research communities, too, are working to better understand the causes and consequences of obesity, with the goal of developing more effective prevention and treatment strategies.

The issue of obesity is part of a broader pattern of rising healthcare costs and changing disease profiles across Europe. The EU has seen significant increases in obesity rates over the past few decades, which are closely linked to other health issues such as diabetes, cardiovascular disease, and certain types of cancer. In response, policymakers have implemented various measures, including taxes on sugary drinks and unhealthy food, to encourage healthier lifestyles. However, these efforts have been met with resistance from some industry groups and consumers, who argue that these measures are too restrictive or ineffective.